CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ranibizumab injection

Last Updated: April 25, 2012
Result type: Reports
Project Number: SR0276
Product Line: Reimbursement Review

Generic Name: Ranibizumab injection

Brand Name: Lucentis

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Macular edema, secondary to retinal vein occlusion

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 18, 2012

Recommendation Type: List with clinical criteria and/or conditions